• Policy
• 6 cases of Ultomiris & 1 case of Spinraza were pre-approved
• by Lee, Hye-Kyung Dec 9, 2021 05:58am

• Policy
• Patients fume over non-deliberation of Kymriah·Keytruda
• by Lee, Jeong-Hwan Dec 9, 2021 05:58am

• Policy
• Impurity detected Cozaar is excluded from recovery
• by Lee, Tak-Sun Dec 8, 2021 06:01am

• Policy
• No recall crisis expected to arise from losartan impurities
• by Lee, Tak-Sun Dec 8, 2021 06:00am

• Company
• Hanmi’s poziotinib enters final phase for commercialization
• by Kim, Jin-Gu Dec 8, 2021 06:00am

• Company
• Hanmi's lung cancer drug Poziotinib has been applied for NDA
• by Kim, Jin-Gu Dec 8, 2021 06:00am

• Company
• The kit for precocious puberty in Korea has been stopped
• by Moon, sung-ho Dec 8, 2021 06:00am

• Company
• Dire need for a rational pricing system for new drugs
• by Nho, Byung Chul Dec 7, 2021 05:57am

• Industry is nervous about strengthening quarantine guideline
• by Kim, Jin-Gu Dec 7, 2021 05:57am

• Company
• Moderna tackles the Omicron variant with booster shots
• by Dec 7, 2021 05:57am